Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Paying $1.53bn Upfront For Zuranolone And SAGE-324
Executive Summary
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.